Radiation Oncology is not the best field in medicine.

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.
As a med student who has had my heart set on rad onc for a while, I hate reading these posts, but they could stop me from making huge career mistake. I appeciate everyone being open about your experiences. The residents at my school say no one regrets their rad onc career choice, but maybe they are delusional.

What do you expect the job market to look like in 10 years from now? Is there any point in hoping that things will sort out, or should I move on and focus more on other specialties I'm considering?

I don't mean to hijack this thread, so just ignore this post if this isn't the place to ask

Members don't see this ad.
 
  • Like
Reactions: 1 users
As a med student who has had my heart set on rad onc for a while, I hate reading these posts, but they could stop me from making huge career mistake. I appeciate everyone being open about your experiences. The residents at my school say no one regrets their rad onc career choice, but maybe they are delusional.

What do you expect the job market to look like in 10 years from now? Is there any point in hoping that things will sort out, or should I move on and focus more on other specialties I'm considering?

I don't mean to hijack this thread, so just ignore this post if this isn't the place to ask
The failure to recognize evil is such a powerful theme in certain great movies. I never wanna be the person who falls into that trap. Here now, you have seen the warnings. Sometimes you can ignore the warnings and everything turns out OK. Other times, it won't turn out OK. Such is life. Choose wisely (ostensibly, tend to avoid radiation, more radiation, etc.)!
 
Last edited:
  • Like
Reactions: 1 user
As a med student who has had my heart set on rad onc for a while, I hate reading these posts, but they could stop me from making huge career mistake. I appeciate everyone being open about your experiences. The residents at my school say no one regrets their rad onc career choice, but maybe they are delusional.

What do you expect the job market to look like in 10 years from now? Is there any point in hoping that things will sort out, or should I move on and focus more on other specialties I'm considering?

I don't mean to hijack this thread, so just ignore this post if this isn't the place to ask

We don’t really know the answer, these are concerns and hypotheses (Do we know if the ABR board pass rate will increase above 50%, guess we don’t know for sure so it’s a concern). But if your career were on the line do you want Michael Jordan or Shaquile O’Neal to take the free throw that determines your fate. Choosing Rad Onc right now is like choosing Shaq to take that free throw, he might make it but it’s not a strong bet.
 
Last edited:
  • Like
Reactions: 1 user
Members don't see this ad :)
We don’t really know the answer, these are concerns and hypotheses (Do we know if the ABR board pass rate will increase above 50%, guess we don’t know for sure so it’s a concern). But if your career were on the line do you want Michael Jordan or Shaquile O’Neal to take the free throw that determines your fate. Choosing Rad Onc right now is like choosing Shaq to take that free throw, he might make it but it’s not a strong bet.
I agree. With so many great specialties out there, should you take this kind of risk. I am an alarmist and believe that within 10 years the job market will be even worse than pathology's without corrective action. I will say this about residents and your first job: most people are somewhat excited no matter the job because for the first time in your life - early 30s-you are getting a real paycheck and not struggling. It takes 1-2 years to "take "inventory," compare yourself, location, and future prospects to others and other specialties.
 
Last edited:
  • Like
Reactions: 2 users
Med school+college is 6 years overseas so first 2 years of foundation training are like our 3/4th year of med school

Well in Europe "med. school" is not applicable, since studying medicine is studying in university like for anything else. So it's university and many students start immediately after high school (18 years old), some may spend some time doing something else after high school (like military service, which is becoming rarer in Europe or some other training / social work) and go to university later.

It's a minimum of 6 years (I had 13 semesters, so that's 6.5 years), but often it can be prolonged if you don't pass all exams at once. The last year is generally "practice orientated", meaning you work at a hospital in rotations and have few to no classes.
After that (around 24-25, if you started at 18) you can start residency, which usually lasts 4-6 years without any special sub-specialization (for example neuroradiology, where you train 2 years on top of the standard radiology residency).

However, you are a lincensed medical physician after finishing those 6 years of university. You simply cannot treat anyone basically, since there is specialization for everything (--> required residency), including general practicioners. But you can "do" stuff doctors are allowed to do, like prescribing medications or writing someone sick and so on...
 
And thus begins our end game. It will be very complex as it will pit private practice vs universities, Insurance companies against hospitals, Med Onc’s, surgeons, and Rad Oncs against each other by specialties and groups. The Bundled payment will get extremely complicated as he who controls the payment wins.... period.

Oncology is far and away the most complicated field in medicine to bundle.... bar none as it also involves pathology, radiology, and all oncology fields including subspecialists ( urology, ENT, GYN, CT surgeons, GI, Neurosurg, and more) but will be tried because of the possible savings involved. I believe insurance companies have the upper hand ( Kaiser, WellPoint, etc) followed by hospitals, and next Med Onc’s. Surgeons and Rad Oncs will be weaker so alliances are important . Few practices are buying new equipment( unless you have a foundation) and hiring is getting cautious.

Why do you think Walmart, Berkshire Hathaway, Amazon, Big Banks( JP Morgan) are all trying to get involved with HealthCare? Trump added a trillion dollars to defense and is looking where he can save money.... Medicare is the obvious target! That is also why McKesson bought US Oncology and Vantage. To ensure it’s own survival of supply chain.

Patrick Soon-Shiong of biotech and pharmacy fame has now bought 6 hospitals in both northern and Southern California . His focus is cancer.....

The big centers: MDA, MSK, Penn, Ohio St, City of Hope, USC and a few others negotiated a sweetheart deal to get paid about 3x more than anyone else

I used to do a lot of permanent seed prostate brachytherapy. It was great with regards to cost , complications and effectiveness. But it died years ago because Medicare stopped paying for seeds and it is little used except in a few places( Seattle....)

The bundled payment if it happens will bring insanity to our field especially if it is manditory. All private practices will be forced to join big groups, hospitals or insurances. Good night to all our autonomy.

The only good thing I see is that oncology is so complex, that bundling will take a few years to actually work, but I don’t believe it will stop the momentum from the government from trying. Just as current Academics don’t care much about the future problems of our young cub rad Onc’s or private practice; they will be more concerned about saving their own necks than they will saving our field. But,meantime we have little hope but to rely on them to give us some voice at the table. To use the Star Wars analogy, we are the rebel fleet as the Death Star approaches . May the rag tag Crew of SDN continue to fight for what is fair and ultimately good for our patients which also our best hope! May the Force be with us all

Long time lurker/rare poster, but hoping I can be of some help by chiming in now. It seemed most relevant to categorize my reply to this post while touching on some of the earlier and later ones. At risk of identifying myself, here are some points, not necessarily replying to Old rad onc:

- Capitation does not equal bundled payments. Capitation is where, for example, a PCP receives $75/mo per patient under his/her service and is responsible for the fees associated with most medical care for his/her patients. A "bundled payment" can be for any set of services and may or may not have significant financial risk built in for the provider. Highly specialized providers like radoncs don't fit a capitated model, and I'd bet large sums of money that we won't receive capitated payments for patients in my lifetime. More to follow.
- The proposed ASTRO RO-APM, currently not approved (though it's likely heading that way), is to deliver a per-patient bundled payment for radiation oncology services for the most common patient types we see. Patient comes for consult, needs (and is going to get) radiation, you receive part of the payment upfront and part on the back end, when the work is done. If you're interested, a description of it is available for free online, via a Google search. We once feared that we'd be receiving bundled payments for cancer patients (e.g. a payment to the center/group of centers to cover a breast cancer patient, and the med/rad/surg oncs have to figure out who gets what), but there is no sign that we're heading that direction for the vast majority of markets. Contracted centers like ACOs may be able to experiment with this in the not so distant future, but IMHO, independent centers/groups will never be forced into that. It is too big of a logistical mess.
- The Oncology Care Model does not cover radiation oncology services. The bundled payments there are for the med oncs' work
- The RO-APM is meant to play nice with the OCM, so that if a patient (sticking to same example, early stage breast cancer patient) needs adjuvant radiation, the med onc or other referring provider is not financially liable for the radiation services.
- The RO-APM works off the prior two years of payments for patients of the given types, for your center/group. Looking back to the usual-and-customary care days from before fee-for-service, I can't imagine there won't be some regional averaging (i.e. it wouldn't make sense to pay different amounts to centers in the same town), and it is my understanding that the historical data part of the RO-APM is how they are planning to maintain the geographic modifier-type system.
- If you get a bundled payment, it will be up to you as to how to treat the patient. Protons? If you're into that. Brachy? Up to you. Frequency of imaging for setup? You'll get the same bundled payment. There will likely be some high-level/superficial surveillance to make sure providers aren't delivering inappropriate care, but I haven't seen that spelled out.
- IMHO, bundled payments will be an exciting era to cut waste at your site. I wouldn't believe anyone who told me they have no waste to cut from their processes. Sure, we won't have the ability to do more and get paid more like fee-for-service, but it'll force people to be more efficient or struggle to succeed.

At risk of being chased with pitch forks, for the future applicants and junior residents reading this:
- I thought the job market was pretty good this year. I targeted 5 desirable cities, and there was at least one job available in 4 of them. A job in the 5th appeared after I signed. I networked early and often. I followed up on cold calls/cold emails regularly, and I found everything I could about docs' personal and professional backgrounds online to establish some commonality with them. No, I did not say "I have to be in [x] city," and I agree with the others that you will likely be disappointed if you put that much pressure on your job search. That said, I am heading to a fantastic location and truly believe I got 3 out of 3 on location, salary, and lifestyle. Best of luck.
 
Long time lurker/rare poster, but hoping I can be of some help by chiming in now. It seemed most relevant to categorize my reply to this post while touching on some of the earlier and later ones. At risk of identifying myself, here are some points, not necessarily replying to Old rad onc:

- Capitation does not equal bundled payments. Capitation is where, for example, a PCP receives $75/mo per patient under his/her service and is responsible for the fees associated with most medical care for his/her patients. A "bundled payment" can be for any set of services and may or may not have significant financial risk built in for the provider. Highly specialized providers like radoncs don't fit a capitated model, and I'd bet large sums of money that we won't receive capitated payments for patients in my lifetime. More to follow.
- The proposed ASTRO RO-APM, currently not approved (though it's likely heading that way), is to deliver a per-patient bundled payment for radiation oncology services for the most common patient types we see. Patient comes for consult, needs (and is going to get) radiation, you receive part of the payment upfront and part on the back end, when the work is done. If you're interested, a description of it is available for free online, via a Google search. We once feared that we'd be receiving bundled payments for cancer patients (e.g. a payment to the center/group of centers to cover a breast cancer patient, and the med/rad/surg oncs have to figure out who gets what), but there is no sign that we're heading that direction for the vast majority of markets. Contracted centers like ACOs may be able to experiment with this in the not so distant future, but IMHO, independent centers/groups will never be forced into that. It is too big of a logistical mess.
- The Oncology Care Model does not cover radiation oncology services. The bundled payments there are for the med oncs' work
- The RO-APM is meant to play nice with the OCM, so that if a patient (sticking to same example, early stage breast cancer patient) needs adjuvant radiation, the med onc or other referring provider is not financially liable for the radiation services.
- The RO-APM works off the prior two years of payments for patients of the given types, for your center/group. Looking back to the usual-and-customary care days from before fee-for-service, I can't imagine there won't be some regional averaging (i.e. it wouldn't make sense to pay different amounts to centers in the same town), and it is my understanding that the historical data part of the RO-APM is how they are planning to maintain the geographic modifier-type system.
- If you get a bundled payment, it will be up to you as to how to treat the patient. Protons? If you're into that. Brachy? Up to you. Frequency of imaging for setup? You'll get the same bundled payment. There will likely be some high-level/superficial surveillance to make sure providers aren't delivering inappropriate care, but I haven't seen that spelled out.
- IMHO, bundled payments will be an exciting era to cut waste at your site. I wouldn't believe anyone who told me they have no waste to cut from their processes. Sure, we won't have the ability to do more and get paid more like fee-for-service, but it'll force people to be more efficient or struggle to succeed.

At risk of being chased with pitch forks, for the future applicants and junior residents reading this:
- I thought the job market was pretty good this year. I targeted 5 desirable cities, and there was at least one job available in 4 of them. A job in the 5th appeared after I signed. I networked early and often. I followed up on cold calls/cold emails regularly, and I found everything I could about docs' personal and professional backgrounds online to establish some commonality with them. No, I did not say "I have to be in [x] city," and I agree with the others that you will likely be disappointed if you put that much pressure on your job search. That said, I am heading to a fantastic location and truly believe I got 3 out of 3 on location, salary, and lifestyle. Best of luck.

Good on you for finding a great place to work. More concerned about what that job will look like in 3 years-5 years or after all this stuff takes effect. I don't think anyone should chase you with pitch forks for speaking about your experience or your opinions.

Are the bundled payments just for specific disease sites? I'm guessing breast, prostate, lung, head and neck, palliative?? I mean just breast and prostate alone you could save the health system massive dollars. Of course, I don't anticipate any RO will see a dime of that savings as they will mostly be working for somebody else.

In the FFS days, they worried about doing too many non beneficial costly interventions to the patient but now that the risk has essentially been transferred to the provider with a fixed payment. Sure you can still recommend what you want until admin and/or your colleagues start hounding why don't you image less on treatment, use a different fractionation scheme, less follow-up post tx, use 3D as opposed to IMRT. Heaven help you if you want to transfer a patient to another institution (money out the door). Some really bold ROs (nobody in this forum) may try unconventional fx schemes off protocol to try to save a bit of money and take the risk of a bad late effect or a recurrence.

No question about the drive for efficiency inherent in these models. It seems to me the way to succeed in this new system will be to find a way to see as many patients as possible and then minimizing the cost per patient. More patient's per attending and a few mid levels to see the OTVs and follow-ups and support staff to keep the unnecessary stuff to a minimum. Honestly, the more I think about it the more it sounds like the life of a GP. I can see getting more aggressive with developing automated processes to keep contouring and planning times to a minimum. Templating everything is kind of a no brainer. Automated QA not sure where they are in that process.

I really don't think its fair to describe a situation where there is a hard push for efficiency as an "exciting" time for anyone in any industry. Just ask workers in the airline industry how deregulation went over (good prices for passengers and hell for the workers), people that worked for Bell before the 80's breakup, GM in the last few days, hell even my own hospital system (went from union wages and pensions to per diems and 401ks with a pittance match) all in the name of efficiency. Trimming the excess is never a fun time even for the higher ups who usually stand gain at least something.

Again, good for you to see the silver lining in all this because I can't. I'm sure you'll be a great attending.
 
I agree that case-based reimbursement for radonc is much, much better than other alternatives, including bundling with other services, capitation, etc. The devil will be in the details, however, and there are a few things about the ASTRO-APM I disagree with.
- Recommending a 3% cut in reimbursement off the bat. I get that stability of payments is worth something, but inflation still exists. I'd rather they would have gone with a freezing of rates with an annual inflation adjustment.
- Once again, ASTRO decided against payment neutrality with respect to site of service, which in my opinion completely destroys any and all credibility they have when it comes to cost control. Payment neutrality is clearly - clearly- the easiest and quickest way to save money throughout the health system. The hypocrisy of developing "choose wisely" campaigns while lobbying against payment neutrality (and also advertising for protons for prostate cancer on my facebook feed- looking at you MDAnderson) is stunning.
 
  • Like
Reactions: 2 users
I agree that case-based reimbursement for radonc is much, much better than other alternatives, including bundling with other services, capitation, etc. The devil will be in the details, however, and there are a few things about the ASTRO-APM I disagree with.
- Recommending a 3% cut in reimbursement off the bat. I get that stability of payments is worth something, but inflation still exists. I'd rather they would have gone with a freezing of rates with an annual inflation adjustment.
- Once again, ASTRO decided against payment neutrality with respect to site of service, which in my opinion completely destroys any and all credibility they have when it comes to cost control. Payment neutrality is clearly - clearly- the easiest and quickest way to save money throughout the health system. The hypocrisy of developing "choose wisely" campaigns while lobbying against payment neutrality (and also advertising for protons for prostate cancer on my facebook feed- looking at you MDAnderson) is stunning.
ASTRO/Choosing Wisely says protons for prostate cancer should only be used in prospective trials or if the patient is on a "registry." (I'm no epidemiologist but I think registries are always retrospective in nature, thus the guideline essentially says prostate patients should only be treated with protons if prospective or retrospective data is being gathered.. I don't know of any other ways to gather patient data... but I digress.) The guideline explicitly states protons are not better than other radiation methods. And yet here we are. Do as I say... not as I do!
 
Endorsement of proton reimbursement for "registry" trials is so deceptive. When CMS considered cuts to protons earlier this year, ASTRO was quick to protest. A 10 year "registry" trial in this setting is truly laughable and not aligned with the public good. If a center treats low risk prostate with protons, they should fund it themselves. A registry trial is backhanded financial abuse. ASTRO is attempting to create legitimacy, a "cover" for treating prostate in the present environment. The best evidence to date is that protons have worse, not equal rectal toxicity.





News > Medscape Medical News > Oncology News
ASTRO Coverage Recommendations for Proton Beam Therapy
Roxanne Nelson, BSN, RN

July 20, 2017

  • policy paper provides guidance to all insurers, including Medicare, Medicaid, and commercial payers, about the clinical indications that are appropriate for proton bean therapy and that should be covered.

    "Recent research has expanded our understanding of the types of malignancies and clinical scenarios where proton beam therapy is most advantageous. This policy update reflects the most current knowledge regarding which patients will benefit from — and therefore should have access to — this cutting-edge treatment," said ASTRO Chair David C. Beyer, MD.

    "We also remain firmly committed to developing evidence to identify new areas where this technology might be beneficial as well as situations where it is not needed," Dr Beyer explained in a statement.

    Controversy Over Use
    Proton beam therapy offers a high degree of precision, allowing an escalated radiation dose to be targeted directly on a tumor while sparing the adjacent healthy tissue. Although not new, the use of proton beam therapy in medical settings has greatly increased during the past decade, but it remains controversial because of cost and also because there is little evidence as to how it compares with other forms of radiotherapy.

    There are currently 11 proton beam therapy centers in North America, and 13 more centers are in development.

    The updated ASTRO guidelines are based on new evidence that was published since the original policy was issued in 2014.

    Recommendations for Coverage
    In the new model, ASTRO identifies two categories for the appropriate use of proton beam therapy.

    For group 1, coverage is recommended; for group 2, coverage is recommended if additional requirements are also met.

    Group 1 indications – for which coverage is recommended – include the following:
    • Both malignant and benign primary central nervous system tumors

    • Advanced and/or unresectable head and neck cancers

    • Malignancies of the paranasal sinuses and other accessory sinuses

    • Retroperitoneal sarcomas that have not metastasized

    • Cases requiring reirradiation but in which the cumulative critical structure dose would exceed tolerance dose

    • Hepatocellular cancer (no longer required to be treated in a hypofractionated regimen)

    • Ocular tumors, including intraocular melanomas

    • Tumors that are close to or located at the base of skull

    • Primary or metastatic spinal tumors in which conventional treatment would exceed tolerance or in cases in which the spinal cord has previously been irradiated

    • Primary or benign solid tumors in children treated with curative intent and for occasional palliative treatment of childhood tumors when one of the criteria noted above apply

    • Patients with genetic syndromes that require minimization of the total volume of radiation, including patients with neurofibromatosis type 1 and those with retinoblastoma
    For group 2, the model policy notes that all other indications not listed in group 1 are suitable for coverage with evidence development (CED). Patients treated under the CED paradigm should be covered by insurance as long as they are enrolled either in an institutional review board–approved clinical trial or in a multi-institutional patient registry that follows Medicare requirements for CED.


    There are currently no indications that are considered inappropriate for CED; group 2 has a number of indications, which include the following:
    • Non-T4 and resectable head and neck cancers

    • Thoracic tumors that include nonmetastatic primary lung and esophageal cancers, as well as mediastinal lymphomas

    • Abdominal tumors that include nonmetastatic primary pancreatic, biliary, and adrenal cancers

    • Pelvic malignancies that include nonmetastatic rectal, anal, bladder, and cervical cancers

    • Nonmetastatic prostate cancer

    • Breast cancer

    The model policy update was developed by ASTRO's Payer Relations Subcommittee. The committee points out that model policies differ from practice guidelines, which are written for physicians and outline recommendations to optimize clinical care.


    ASTRO. ASTRO Model Policies: Proton Beam Therapy (PBT). Full text


    Follow Medscape Oncology on Twitter for more cancer news: @MedscapeOnc
 
Last edited:
Long time lurker/rare poster, but hoping I can be of some help by chiming in now. It seemed most relevant to categorize my reply to this post while touching on some of the earlier and later ones. At risk of identifying myself, here are some points, not necessarily replying to Old rad onc:

Yes I am sure that some people will get good jobs, but the macroscopic picture is unchanged. Radiation utilization in the UK is similar to the US in terms of number of pts (if anything, I find european docs more radiation friendly hodgkind/bladder/mets, but less fractions). About 230 cases per 100,000. That is enough- actually a little less- for one doc on average, although many/most of us see more than that per year: www.ncin.org.uk/view?rid=3426
 
Last edited:
Derm matches more than 23 a year
The article only considers PGY-1 positions (which is probably a mistake as many of the "competitive specialties" start training PGY-2 and a minority have integrated PGY-1 years). For example, RadOnc has 16 PGY-1 positions and 177 PGY-2 positions.
Simple analysis that doesn't tell the whole picture but it supports the poster's bias so let's use it.
 
  • Like
Reactions: 1 user
.
Simple analysis that doesn't tell the whole picture but it supports the poster's bias so let's use it.
I don't disagree with it though, I imagine RO has in fact dropped in competitiveness compared to ent, plastics, derm etc over the last few years if we look at aggregate spots per year in all those specialities
 
Last edited:
upload_2018-12-2_16-33-3.png


The above is from 2018. Will be of interest to watch over the next few years.
 
Base on ERAS prelim data, 191 US grads applied this year. 225 applied in 2018. There are 193 positions in rad onc in 2018. So this year there are more positions than US grads.
 
  • Like
Reactions: 1 users
Base on ERAS prelim data, 191 US grads applied this year. 225 applied in 2018. There are 193 positions in rad onc in 2018. So this year there are more positions than US grads.
To be exact (forgive me) the number of NRMP positions in the 2019 Match will not be finalized until the programs enter their quota (which is late January). It may well be that the number of positions is greater than the number of US grads but we cannot know this until after the programs list their quota with the DIO and subsequently NRMP.
 
Top